BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Weich A, Serfling SE, Yi H, Buck AK, Higuchi T, Werner RA. Complete Remission Upon Peptide Receptor Radionuclide Therapy in a G2 Pancreatic Neuroendocrine Tumor. Clin Nucl Med 2023. [PMID: 36728231 DOI: 10.1097/RLU.0000000000004537] [Reference Citation Analysis]
2 Virarkar MK, Montanarella M, Itani M, Calimano-ramirez L, Gopireddy D, Bhosale P. PET/MRI imaging in neuroendocrine neoplasm. Abdom Radiol 2022. [DOI: 10.1007/s00261-022-03757-1] [Reference Citation Analysis]
3 Rajamohan N, Khasawneh H, Singh A, Suman G, Johnson GB, Majumder S, Halfdanarson TR, Goenka AH. PET/CT and PET/MRI in neuroendocrine neoplasms. Abdom Radiol (NY) 2022;47:4058-72. [PMID: 35426497 DOI: 10.1007/s00261-022-03516-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Szidonya L, Park EA, Kwak JJ, Mallak N. Molecular and Anatomic Imaging of Neuroendocrine Tumors. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2022.06.009] [Reference Citation Analysis]
5 Liu Z, Kong Y, Dang Q, Weng S, Zheng Y, Ren Y, Lv J, Li N, Han Y, Han X. Liquid Biopsy in Pre-Metastatic Niche: From Molecular Mechanism to Clinical Application. Front Immunol 2022;13:958360. [DOI: 10.3389/fimmu.2022.958360] [Reference Citation Analysis]
6 Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S, Pappagallo G, Seregni E, Versari A. Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers (Basel) 2022;14:2501. [PMID: 35626105 DOI: 10.3390/cancers14102501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lee ONY, Tan KV, Tripathi V, Yuan H, Chan WW, Chiu KWH. The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med 2022. [PMID: 35485851 DOI: 10.1097/RLU.0000000000004235] [Reference Citation Analysis]
8 Fang H, Shi K, Wang X, Zuo C, Lan X. Editorial: Artificial Intelligence in Positron Emission Tomography. Front Med 2022;9:848336. [DOI: 10.3389/fmed.2022.848336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Galgano SJ, Iravani A, Bodei L, El-haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response— AJR Expert Panel Narrative Review. American Journal of Roentgenology. [DOI: 10.2214/ajr.21.27159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
10 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]